

Index

Note: An *f* following a page number refers to a figure on that page; a *t* following a page number refers to a table following that page.

- adaptive
 - eligibility, 55–57
 - randomization, 31
- adaptive signature design, 72–73, 74
 - cross-validated, 75–79
 - fall-back test, 47–48
- adaptive threshold design, 59–63
 - probabilistic indication classifier and, 60–62
 - sample size planning, 62–63
- aggregated Classification Trees, 117
- algorithms
 - class prediction, 112–118
 - genetic, 114
 - pre-specified algorithmic analysis plan, 72
- analytical validity, 11, 88
- baseline cumulative hazard, 122–123
- baseline hazard function, 30, 120
- Battle I trial in advanced non-small cell
 - lung cancer, 30–33
 - results of, 31*t*, 31–32
 - two-stage design, 32–33
- Bayesian methods, 101–103
 - adaptive designs for randomized phase II trials, 30–33
 - computing posterior probabilities, 102–103
 - estimating sensitivity and specificity, 124
 - frequentist methods *versus*, 101–102
 - loss function, 102–103
 - non-informative prior distributions, 103
 - posterior distributions, 102
 - prior distributions, 102, 103
 - probabilistic indication classifier, 61
 - Type I error, 103
 - usefulness in phase 3 trials, 103
- binary disease classification, 124–125
- biomarkers. *See* predictive biomarkers; prognostic biomarkers
- blinding
 - assay to clinical data, 87, 88
 - results of interim analyses, 5
- bootstrapping, 61, 66, 79
- BRB-ArrayTools software, 125
- breast cancer
 - enrichment design and trastuzumab, 39
 - MammaPrint score, 11, 22, 33
 - Oncotype DX recurrence score, 11, 22–23, 35
 - TAILORx clinical trial, 22–23, 35, 86

140 **Index**

- calibration, 119–120
- class comparison, 105–106, 107
- class discovery, 105–106
- class labels, 107–108, 109, 110, 111
- class prediction, 105
 - bias in estimate of error rates, 111
 - components of, 107–108
 - cross-validation, 68, 109–111
 - leave-one-out-cross-validation, 109–111
 - definition of, 107–108
 - estimating accuracy of, 108–112
 - feature selection, 108, 113–114
 - mathematical classifier function, 108, 112–118
 - classification trees, 117
 - compound covariate, 70, 116
 - Fisher discriminant analysis, 115, 116
 - k-nearest neighbor, 117
 - nearest centroid classification, 117
 - nearest neighbor classification, 116, 117–118, 125
 - support vector machines, 116
 - weighted voting classifier, 69, 116
 - misclassification rate, 116, 118
 - parameter specification, 108
- clinical trials. *See* phase 1 trials; phase 2 trials; phase 3 trials
- clinical validity, 11, 85
- cluster analysis, 106
- companion diagnostic, 35–36, 88
- Compound Covariate Predictor, 116
- confidence interval, 66, 94–95
- covariance matrix, 71, 99, 100, 119
- Cox's proportional hazard model. *See* proportional hazards model
- cross-validated Kaplan-Meier curves, 19f, 121–123, 127
- cross-validation, 68, 109–111
 - adaptive signature design, 75–79
 - error rate, 110–111
 - leave-one-out-cross-validation, 109–111
 - log-rank statistic, 128
 - 10-fold cross-validation, 78
- data safety monitoring committee, 5
- diagonal linear discriminant analysis, 115–116
- enrichment design, 35–43
 - sample size planning, 42–43
 - standard design *versus*, 36–40
 - test performance/specificity, influence on, 40
- trastuzumab study, 39
- fall-back analysis, 47–48
- false negatives
 - in enrichment designs, 42
 - in intention to treat analysis, 2
 - in optimal two-stage design, 26
- false positives
 - in gene detection, 12–13
 - in intention to treat analysis, 2
 - in optimal two-stage design, 26
- feature selection
 - class prediction, 108, 113–114
 - univariate gene selection, 79
- Fisher linear discriminant analysis, 115
- futility analysis, interim, 50, 56–57
- gene finding, for prognostic classifier, 12–13
- Gene Expression Omnibus, 78
- gene expression profiles, to
 - develop/validate prognostic classifiers, 105–128
- gene shaving, 114

141 **Index**

- genetic algorithms, 114
 genomics, vii, 46, 89
 goodness of fit, 13–14
- hazard function. *See* proportional hazards model
- indication classifier, 46–47
 intention to treat, 2
 interaction design, 48
 interaction tests, 48–49, 54
 interim futility analysis, 50, 55–57
 intermediate endpoint, 1, 25, 57
- k-nearest neighbor classification, 117
 Kaplan-Meier survival curves, 14–15, 16f, 18, 96, 121, 125
 cross-validated Kaplan-Meier curves, 19f, 121–123, 127
 KRAS mutation status, 35, 83, 88
- L1 penalized proportional hazards regression, 127
- labels, class, 107–108, 109, 110, 111
- leave-one-out-cross-validation (LOOCV), 109–111
- likelihood
 full likelihood, 99
 maximum, 98, 99
 partial, 100
- linear discriminant analysis, 115–116
 linear regression, 97, 98
 LOE (Level of Evidence) Scale, 83
 log-rank test, 76–79
 cross-validated statistic, 128
 logistic regression, 28–29, 99
- MammaPrint score, 11, 22, 33
 Mann Whitney test, 113
- marker strategy design, 21f, 20–21
 matrix, covariance, 71, 99, 100, 119
 maximum likelihood, 98, 99
 medical utility, 11, 20, 85
 microarray analysis, 78. *See also*
 prognostic classifiers, based on high dimensional data
 MINDACT clinical trial, 22–23
 misclassification rate, 116, 118
 modified marker strategy design, 22f, 21–22, 23
 molecularly targeted drugs, 1
 multicenter clinical trials, 5
- nearest centroid classification, 117
 nearest neighbor classification, 116, 117–118, 125
 nearest shrunken centroid classification, 118–119
 noise variables, 108
 non-informative prior distributions, 103
 nonparametric tests, 93
- Oncotype DX recurrence score, 11, 22–23, 35
 one-sided p-value, 3
 optimal two-stage phase II design, 32–33
 over-fitting, 68
- p-value, 3
 one-sided, 3
 two-sided, 3
 partial least squares, 114, 120–121
 partial likelihood, 100
 penalized logistic regression models, 72, 119
 permutation test, 65–67, 91–93

142 **Index**

- phase 2 trials, 25–33
 - Battle I trial in advanced non-small cell lung cancer, 30–33
 - Bayesian adaptive designs for randomized phase 2 trials, 30–33
 - endpoint as progression-free survival, 30
 - logistic regression analysis, multiple candidate biomarkers, 28–29
 - predictive biomarker design, single candidate binary, 26–28
 - predictive biomarkers design, one or more binary candidates, 26
 - purpose of, 1, 25–26
 - two-stage design, 26
- phase 3 trials
 - endpoint, 2
 - intention to treat principle, 2
 - interim analyses, 4–5
 - overview of, 1–5
 - pivotal, 36
 - power, 3–4
 - purpose of, 45
 - sample size, 3–4
 - statistical significance of, 3
 - subset analyses, 5
- population sampling model, 93–94
- pre-specified algorithmic analysis plan, 72
- predictive biomarkers
 - designs based on single candidate biomarkers, 65–68
 - designs for development/validation of multivariate classifiers, 68–79
 - identification and validation of, 35–36
 - logistic regression model, 28–29
 - molecularly targeted therapy, 25, 53
 - multiple, 65–79
 - one or more binary candidates, 26
 - predictive classifiers, 68
 - single candidate, 26–28
 - and study size, 4
- predictive classifiers
 - defining, 35
 - development of, 106–107
 - fall-back analysis and, 47–48
 - indication classifier, 46–48
 - randomized trial comparing new drug to control regimen, 36
 - test performance/specificity, influence on enrichment design, 40
- predictive pre-specified binary classifier, test positive/test negative patients, 45–57
 - adaptively modifying types of patients accrued, 55–57
 - interaction tests, 48–49
 - probabilistic indication classifier, 49–52
 - sample size planning, 52–55
- probabilistic indication classifier, 49–52
 - adaptive threshold design and, 60
 - evaluation of sensitivity/specificity of classifier, 52
- probability of early termination (PET), 32*t*, 33*t*
- probabilistic class prediction, 118–120
 - refinement, 119–120
- prognostic biomarkers
 - classification error, 13
 - false discoveries, 12–13
 - goodness of fit and, 13–14
 - medical utility of, 11
 - sample size, 13
 - split-sample approach to avoid bias, 14–15. *See also* prognostic classifiers
- prognostic classifiers
 - based on high dimensional data, 105–128

143 **Index**

- combined models, 127–128
- evaluating whether, improves on
 - existing prognostic factors, 126–128
- marker strategy design, 20–21, 21*f*
- medical utility of, 20
- modified marker strategy design, 22*f*, 21–22, 23
- univariate gene selection, 79
- validation studies of, 20–23
- prognostic factor studies, 11
- proportional hazards model, 96–97, 99–101, 120
 - baseline cumulative hazard, 122–123
 - baseline hazard function, 30, 120
 - endpoint as progression-free survival, 30
 - hazard function, 96, 100
 - hazard ratio, 15
 - L1 penalized proportional hazards regression, 127
 - sample size planning, 4
- prospective-retrospective design, 83–85
- randomization
 - adaptive, 31
 - Bayesian designs and, 30–33, 49–50
 - stratified, 30, 45
- re-sampling, 14, 125
- re-substitution estimate, 111–112
 - of error rate, 111–112
- regression modeling, 11, 97
 - linear regression, 97, 98
 - logistic regression, 28–29, 99
 - proportional hazards regression, 99–101
- right-censored data. *See* survival data
- ROC (receiver operating characteristic) curve, 124–125
 - cross-validated ROC, 125
- sample size planning, 12–13, 52–55
 - and adaptive randomization, 31
 - adaptive threshold design, 62–63
 - enrichment design, 42–43
 - optimal two-stage design, 32–33
 - proportional hazards model, 4
- sample splitting, 68
- shrunk centroid classification, 117
- split-sample method, 109
- statistical power, 3–4, 96
- statistical significance, 91–94
 - one-sided p-value, 3
 - permutation significance test, 65–67
 - threshold significance level, 4–5, 12, 113
 - two-sided p-value, 3
- stratification design, 45
- strong null hypothesis, 59–60, 76
- study-wise type I error, 48–49
- supervised principle component classifier, 114
- support vector machines (SVMs), 116
- survival analysis, 96–97
- survival risk prediction, 120–125
 - cross-validated Kaplan-Meier curves, 19*f*, 121–123, 127
 - Kaplan-Meier survival curves, 14–15, 16*f*, 18, 96
 - survival risk classifiers, 120–121
 - time-dependent receiver operating characteristic curves, 124–125
- t-test, 113
- TAILORx clinical trial, 22–23, 35, 86
- threshold significance level, 4–5, 12, 113
- time-dependent receiver operating characteristic curves, 124–125
- time-to-event endpoint, 54–55, 76–79
- tuning parameters, 108
- two-way analysis of variance, 48

144 **Index**

- type I error, 5, 83
 - in adaptive signature design, 73
 - and Bayesian methods, 103
 - defined, 4–5
 - study-wise, 48–49
 - two-sided, 12
 - without specifying cut-point in advance, 60
- validity
 - analytical, 11, 88
 - calibration as measure of, 119–120
 - clinical, 11, 85
 - medical utility, 11, 20, 85
 - of regression model, 101
 - validation studies of prognostic classifiers, 20–23